Welcome to our dedicated page for Emergent Biosolutions news (Ticker: EBS), a resource for investors and traders seeking the latest updates and insights on Emergent Biosolutions stock.
Emergent BioSolutions develops and supplies public health products and medical countermeasures for government agencies, healthcare providers, and community preparedness programs. Its news centers on products such as NARCAN® Nasal Spray for opioid overdose emergencies and ACAM2000® for smallpox and mpox, along with biodefense countermeasures for threats including anthrax, botulism, and Ebola.
Recurring updates also cover quarterly results, debt refinancing and balance-sheet actions, regulatory approvals, government supply activity, and manufacturing services. The company reports on bioservices agreements and facility utilization at sites such as Canton, Massachusetts, and Winnipeg, Manitoba, where it supports vaccine, biologic, and drug product manufacturing programs.
Emergent BioSolutions Inc. (NYSE: EBS) has secured approximately $400 million in orders for 2024 and 2025 related to its vaccinia, smallpox, and mpox product portfolio. This includes a U.S. government contract modification for ACAM2000® and CNJ-016® (VIGIV) contract options. In 2024, nearly $210 million in orders have been delivered, with an additional $185+ million confirmed for delivery through 2025.
The company recently received FDA approval for ACAM2000® to include mpox prevention in high-risk individuals. Emergent has also submitted an Expression of Interest to the WHO for Emergency Use Listing (EUL) of ACAM2000® for mpox. Additionally, Emergent has donated 50,000 doses of ACAM2000® for potential deployment in affected African countries.
Emergent BioSolutions Inc. (NYSE: EBS) has been awarded a $41.9 million contract modification by BARDA for the continued development of Ebanga™ (ansuvimab-zykl), a licensed treatment for Ebola virus disease. This option is part of a larger 10-year contract valued at approximately $121 million for advanced development and up to $583 million for procurement of Ebanga™ treatment.
The funding will support drug substance engineering, scale-up process validation, long-term stability studies, and commercial readiness. Emergent will also complete post-licensure commitments, including technology transfer for manufacturing scale-up and submission of a supplemental Biologics License Application to the FDA.
Emergent BioSolutions Inc. (NYSE: EBS) has successfully refinanced its debt, closing a new credit facility agreement with Oak Hill Advisors for a term loan of up to $250 million. The New Term Loan, maturing in August 2029, replaces the previous credit agreement scheduled to mature in May 2025. This refinancing is part of Emergent's multi-year plan to stabilize, turnaround, and transform the company.
Key points include:
- Excess proceeds will add cash to the balance sheet
- Emergent issued warrants to purchase 2.5 million shares of common stock
- The company agreed to issue $10 million worth of common stock to lenders
- Emergent is on track to reduce net debt by over $200 million this year
This refinancing provides Emergent with additional liquidity and flexibility to execute its business plan and continue providing critical, life-saving products.
Emergent BioSolutions (NYSE: EBS) has launched the second year of its Ready to Rescue initiative, expanding efforts to increase awareness and availability of NARCAN® Nasal Spray for opioid emergency preparedness. The campaign, featuring pro football legend Emmitt Smith, will include new college football tailgate stops, in-stadium activities, Greek Life events, and student wellness clinics.
The initiative aims to educate communities on opioid risks and how to be prepared with NARCAN® Nasal Spray, which is now available over-the-counter. Targeting college communities, where opioid misuse and dependency rates are highest among 18-25 year-olds, the campaign will visit several universities this fall to provide education and Ready to Rescue kits.
Emergent emphasizes the importance of widespread access to NARCAN® Nasal Spray, as opioid poisonings remain the leading cause of accidental death in the United States, despite a recent reduction in drug overdose deaths.
Emergent BioSolutions Inc. (NYSE: EBS) announced that the FDA has approved ACAM2000® for prevention of mpox disease in high-risk individuals. This single-dose vaccine, originally approved for smallpox in 2007, now has an expanded indication. The approval is based on human safety data and animal studies showing effectiveness against mpox virus exposure.
Emergent is actively engaging with global health leaders to support the response to the recent mpox outbreak, which the WHO declared a public health emergency. The company plans to donate 50,000 doses of ACAM2000® for potential deployment in Central Africa. This approval comes as mpox continues to spread, with over 95,000 cases reported across 115 non-endemic countries in 2022.
Emergent BioSolutions Inc. (NYSE: EBS) has finalized the sale of its Baltimore-Camden drug product facility to Bora Pharmaceuticals Co., (TWSE: 6472) for approximately $30 million, subject to post-closing adjustments. The transaction includes the transfer of assets, equipment, and workforce associated with the 87,000 square foot manufacturing site. This sale is part of Emergent's multi-year plan to stabilize, turnaround, and transform the company, with a focus on improving profitability and reducing debt. Joe Papa, President and CEO of Emergent, emphasized the significance of this milestone in creating a more customer-focused, leaner, and flexible organization.
Emergent BioSolutions (NYSE: EBS) is responding to the mpox public health emergency in Africa by donating 50,000 doses of its ACAM2000® vaccine through Direct Relief. This action follows the WHO's declaration of a public health emergency of international concern (PHEIC) due to the mpox outbreak in Central Africa. Emergent has filed a supplemental Biologics License Application (sBLA) with the FDA to expand ACAM2000®'s indication to include immunization against mpox virus, with a review target in Q3 2024.
The company is actively engaging with global health leaders and has the capacity to increase supply by approximately 40 million doses if needed. Emergent emphasizes the importance of ongoing efforts to produce and stockpile vaccines for orthopox viruses, including mpox and smallpox, in light of increasing outbreaks worldwide.
Emergent BioSolutions (NYSE: EBS) reported Q2 2024 financial results with total revenues of $254.7 million, above prior guidance. The company posted a net loss of $283.1 million and adjusted EBITDA of $(10.1) million. Key highlights include:
- Secured $250 million in U.S. government contract modifications for medical countermeasures
- Announced $30 million agreement to sell Baltimore-Camden manufacturing site
- Received $50 million from resolving contract dispute with Janssen Pharmaceuticals
- Updated FY 2024 guidance: Total revenues of $1,050-$1,125 million, net loss of $(314)-$(274) million
NARCAN® nasal spray sales decreased 10% to $120 million. Anthrax MCM sales increased 83% to $38.7 million, while Smallpox MCM sales fell 86% to $17.9 million. The company expects to exceed $200 million in debt reduction by year-end.
Emergent BioSolutions Inc. (NYSE: EBS) has expanded its distribution capabilities for NARCAN® Nasal Spray by opening a new NARCANDirect™ distribution center in Nevada. This expansion aims to enhance customer delivery experiences across the United States, particularly for West Coast customers. The move is part of Emergent's commitment to broadening access to naloxone nationwide and meeting the increased demand for opioid emergency preparedness.
Key points:
- NARCANDirect™ is an online portal for qualified direct purchasers
- Approximately 64 million doses of NARCAN® Nasal Spray distributed since 2016
- In 2023, Emergent delivered about 11 million cartons (~22 million doses)
- The company is committed to ensuring broad access and strong supply in 2024
Emergent BioSolutions Inc. (NYSE: EBS) has sold its RSDL® (Reactive Skin Decontamination Lotion) kit to SERB Pharmaceuticals for $75 million, with an additional $5 million milestone payment potential. The deal includes SERB acquiring Emergent's leased manufacturing facility in Hattiesburg, Mississippi, along with site-based employees and product inventory. Emergent's Winnipeg facility will continue to supply bulk lotion to SERB under a long-term agreement.
This sale is part of Emergent's multi-year plan to reduce debt and improve financial health. The company expects to decrease its debt by over $150 million in 2024 through various measures, including this divestment. The proceeds will help reduce or eliminate Junior Capital Raise requirements under Emergent's amended credit facility, which has been extended to September 29, 2024.